ALK and non-small cell lung carcinoma: In its phase I clinical trial, iruplinalkib was associated with ORRs of 81.0% and 76.3% in patients with treatment-naïve ALK-positive NSCLC in the dose-escalation and -expansion phases, respectively, and with ORRs of 38.1% and 45.7% in patients who had previously received crizotinib in the dose-escalation and -expansion phases, respectively.64